Taysha Gene Therapies, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Taysha Gene Therapies, Inc. (TSHA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$46.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-11
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$46.64M.
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$42.41M.
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$27.85M.
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$32.73M.
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$109.00M.
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$89.30M.
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$111.57M.
- Taysha Gene Therapies, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$166.01M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$46.64M 10-Q · filed 2026-08-11 | -$89.05M 10-Q · filed 2026-08-11 | -$116.90M derived: sum of 3 quarters · filed 2026-08-11 | -$149.63M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$42.41M 10-Q · filed 2026-05-06 | -$70.26M derived: sum of 2 quarters · filed 2026-05-06 | -$102.99M derived: sum of 3 quarters · filed 2026-05-06 | -$129.88M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | -$27.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$60.58M derived: sum of 2 quarters · filed 2026-03-19 | -$87.47M derived: sum of 3 quarters · filed 2026-08-11 | -$109.00M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$32.73M 10-Q · filed 2025-11-04 | -$59.62M derived: sum of 2 quarters · filed 2026-08-11 | -$81.14M 10-Q · filed 2025-11-04 | -$99.93M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | -$26.88M 10-Q · filed 2026-08-11 | -$48.41M 10-Q · filed 2026-08-11 | -$67.20M derived: sum of 3 quarters · filed 2026-08-11 | -$92.72M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$21.53M 10-Q · filed 2026-05-06 | -$40.31M derived: sum of 2 quarters · filed 2026-05-06 | -$65.84M derived: sum of 3 quarters · filed 2026-05-06 | -$86.77M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$18.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$44.31M derived: sum of 2 quarters · filed 2026-03-19 | -$65.24M derived: sum of 3 quarters · filed 2026-03-19 | -$89.30M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$25.52M 10-Q · filed 2025-11-04 | -$46.45M derived: sum of 2 quarters · filed 2025-11-04 | -$70.51M 10-Q · filed 2025-11-04 | -$22.77M derived: sum of 4 quarters · filed 2025-11-04 | |||
| 2024-06-30 | -$20.93M 10-Q · filed 2025-08-12 | -$44.99M 10-Q · filed 2025-08-12 | $2.75M derived: sum of 3 quarters · filed 2025-08-12 | -$114.33M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | -$24.06M 10-Q · filed 2025-05-15 | $23.68M derived: sum of 2 quarters · filed 2025-05-15 | -$93.41M derived: sum of 3 quarters · filed 2025-05-15 | -$118.00M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $47.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$69.35M derived: sum of 2 quarters · filed 2025-02-26 | -$93.94M derived: sum of 3 quarters · filed 2025-02-26 | -$111.57M 10-K · filed 2025-02-26 | |||
| 2023-09-30 | -$117.09M 10-Q · filed 2024-11-13 | -$141.69M derived: sum of 2 quarters · filed 2024-11-13 | -$159.31M 10-Q · filed 2024-11-13 | -$214.38M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$24.60M 10-Q · filed 2024-08-12 | -$42.22M 10-Q · filed 2024-08-12 | -$97.30M derived: sum of 3 quarters · filed 2024-08-12 | -$123.83M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | -$17.62M 10-Q · filed 2024-05-14 | -$72.70M derived: sum of 2 quarters · filed 2024-05-14 | -$99.23M derived: sum of 3 quarters · filed 2024-05-14 | -$133.32M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | -$55.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$81.61M derived: sum of 2 quarters · filed 2024-03-19 | -$115.70M derived: sum of 3 quarters · filed 2024-03-19 | -$166.01M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | -$26.53M 10-Q · filed 2023-11-14 | -$26.31M 10-Q · filed 2022-11-08 | -$60.62M derived: sum of 2 quarters · filed 2023-11-14 | -$110.94M 10-Q · filed 2023-11-14 | -$110.29M 10-Q · filed 2022-11-08 | -$161.32M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$34.09M 10-Q · filed 2023-08-14 | -$33.87M 10-Q · filed 2022-08-11 | -$84.41M 10-Q · filed 2023-08-14 | -$83.98M 10-Q · filed 2022-08-11 | -$134.79M derived: sum of 3 quarters · filed 2023-08-14 | -$185.98M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$50.32M 10-Q · filed 2023-05-11 | -$50.11M 10-Q · filed 2022-05-16 | -$100.70M derived: sum of 2 quarters · filed 2023-05-11 | -$151.89M derived: sum of 3 quarters · filed 2023-05-11 | -$192.82M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$50.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$101.57M derived: sum of 2 quarters · filed 2023-03-28 | -$142.50M derived: sum of 3 quarters · filed 2023-03-28 | -$174.52M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | -$51.19M 10-Q · filed 2022-11-08 | -$92.11M derived: sum of 2 quarters · filed 2022-11-08 | -$124.14M 10-Q · filed 2022-11-08 | -$142.46M derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | -$40.93M 10-Q · filed 2022-08-11 | -$72.95M 10-Q · filed 2022-08-11 | -$91.27M derived: sum of 3 quarters · filed 2022-08-11 | -$106.31M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | -$32.02M 10-Q · filed 2022-05-16 | -$50.34M derived: sum of 2 quarters · filed 2022-05-16 | -$65.38M derived: sum of 3 quarters · filed 2022-05-16 | -$86.60M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$18.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$33.36M derived: sum of 2 quarters · filed 2022-03-31 | -$54.58M derived: sum of 3 quarters · filed 2022-03-31 | -$60.01M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | -$15.04M 10-Q · filed 2021-11-10 | -$36.26M derived: sum of 2 quarters · filed 2021-11-10 | -$41.69M 10-Q · filed 2021-11-10 | -$42.81M derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | -$21.22M 10-Q · filed 2021-08-16 | -$26.65M 10-Q · filed 2021-08-16 | -$27.77M derived: sum of 3 quarters · filed 2021-08-16 | ||||
| 2020-03-31 | -$5.43M 10-Q · filed 2021-05-11 | -$6.55M derived: sum of 2 quarters · filed 2021-05-11 | |||||
| 2019-12-31 | -$1.11M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |